Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Jagsonpal Pharmaceuticals Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 21, 2024, 9:59 pm

Market Cap 1,565 Cr.
Current Price 593
High / Low635/270
Stock P/E58.5
Book Value 74.4
Dividend Yield0.84 %
ROCE17.0 %
ROE13.0 %
Face Value 5.00
PEG Ratio2.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Jagsonpal Pharmaceuticals Ltd

Competitors of Jagsonpal Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,465 Cr. 318390/10865.7 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 59.8 Cr. 80.694.9/25.822.9 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 85.5 Cr. 114155/87.012.8 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,221 Cr. 1,0801,335/62031.2 2072.08 %28.1 %21.1 % 2.00
Industry Average19,460.76 Cr1,177.0554.20184.880.33%16.40%16.92%6.61

All Competitor Stocks of Jagsonpal Pharmaceuticals Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales57.1042.8454.0559.4954.4751.2360.6060.5360.1455.4560.1557.8347.25
Expenses50.6137.7244.7750.0948.8550.4553.4247.6251.5050.0151.5249.4643.85
Operating Profit6.495.129.289.405.620.787.1812.918.645.448.638.373.40
OPM %11.37%11.95%17.17%15.80%10.32%1.52%11.85%21.33%14.37%9.81%14.35%14.47%7.20%
Other Income0.532.660.820.281.950.37-3.151.121.742.562.002.272.52
Interest0.140.130.110.060.060.060.010.030.180.200.150.220.23
Depreciation0.270.260.280.230.370.650.190.200.330.480.390.460.41
Profit before tax6.617.399.719.397.140.443.8313.809.877.3210.099.965.28
Tax %17.85%30.85%29.45%30.24%24.23%31.82%23.50%24.49%21.07%23.50%25.87%25.00%24.81%
Net Profit5.435.106.856.565.410.312.9210.417.795.607.487.473.96
EPS in Rs2.071.952.612.502.070.121.113.972.972.142.862.851.51

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales177166144138143144127167159188218237234
Expenses160156133129132138138157150169192202202
Operating Profit1710119126-119919263531
OPM %9%6%7%6%8%4%-9%6%5%10%12%15%13%
Other Income00001130134329
Interest4554531111001
Depreciation3333320111212
Profit before tax10332414-129922273537
Tax %26%28%16%30%20%18%1%20%16%22%29%23%
Net Profit7221312-127817192728
EPS in Rs2.850.700.810.451.244.53-4.412.763.006.517.2010.2010.82
Dividend Payout %18%72%62%22%8%2%-2%9%17%15%56%49%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)-71.43%0.00%-50.00%200.00%300.00%-200.00%158.33%14.29%112.50%11.76%42.11%
Change in YoY Net Profit Growth (%)0.00%71.43%-50.00%250.00%100.00%-500.00%358.33%-144.05%98.21%-100.74%30.34%

Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:4%
5 Years:5%
3 Years:4%
TTM:-3%
Compounded Profit Growth
10 Years:27%
5 Years:25%
3 Years:10%
TTM:-6%
Stock Price CAGR
10 Years:34%
5 Years:87%
3 Years:58%
1 Year:53%
Return on Equity
10 Years:8%
5 Years:14%
3 Years:16%
Last Year:13%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 10:32 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital13131313131313131313131313
Reserves8585828597859198109120146174184
Borrowings333639388845706910
Other Liabilities21221922252328313531302151
Total Liabilities153156154159143130136147164164195217258
Fixed Assets5856525222212222262324999
CWIP2200034400000
Investments0000000111551100
Other Assets929810210812110511010912391170208159
Total Assets153156154159143130136147164164195217258

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +12849-3-231112874735
Cash from Investing Activity +-3-1-0-241-3-1-11-2-26-58-25
Cash from Financing Activity +-8-4-1-6-34-1-6-1-7-18-0-9
Net Cash Flow02215-624-019-36-112

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow17.00-23.00-25.00-30.00-26.00-2.00-19.005.004.0012.0026.0029.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days9311511910610073454925263219
Inventory Days1271731762462953071641911341228268
Days Payable282942605654597682766635
Cash Conversion Cycle19225925229233932515016477724853
Working Capital Days130155171169174173766645593659
ROCE %6%6%5%7%3%-10%9%9%18%20%25%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters70.34%70.34%68.71%68.71%68.72%68.72%68.72%68.72%68.72%68.48%68.09%68.04%
FIIs0.11%0.20%0.00%0.00%0.13%0.11%0.10%0.37%0.38%0.53%0.73%1.10%
DIIs0.01%0.00%0.67%0.68%0.28%0.77%0.82%0.82%0.82%0.82%0.84%0.84%
Public29.54%29.46%30.61%30.61%30.85%30.40%30.34%30.07%30.07%30.16%30.33%30.01%
No. of Shareholders14,35320,03117,10016,19414,95214,53514,08413,78216,04115,78516,28215,748

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF830.040832024-11-160%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue5.005.005.005.005.00
Basic EPS (Rs.)8.4910.207.486.513.00
Diluted EPS (Rs.)8.4610.207.486.513.00
Cash EPS (Rs.)9.1310.668.066.713.44
Book Value[Excl.RevalReserv]/Share (Rs.)70.8860.6546.9643.5539.39
Book Value[Incl.RevalReserv]/Share (Rs.)70.8860.6549.9546.5442.38
Dividend / Share (Rs.)5.005.004.001.000.50
Revenue From Operations / Share (Rs.)78.9490.3686.3071.7460.53
PBDIT / Share (Rs.)12.2315.2211.128.964.22
PBIT / Share (Rs.)11.6114.7610.548.763.79
PBT / Share (Rs.)11.3013.2910.438.353.59
Net Profit / Share (Rs.)8.5010.207.486.513.00
PBDIT Margin (%)15.4916.8412.8812.486.97
PBIT Margin (%)14.7016.3412.2012.216.26
PBT Margin (%)14.3114.7012.0811.635.93
Net Profit Margin (%)10.7611.288.669.074.96
Return on Networth / Equity (%)11.9816.8115.9214.957.62
Return on Capital Employeed (%)15.5023.1020.5518.548.69
Return On Assets (%)10.3413.7011.6210.385.35
Total Debt / Equity (X)0.000.000.000.050.04
Asset Turnover Ratio (%)1.011.301.361.211.12
Current Ratio (X)10.425.973.242.982.89
Quick Ratio (X)9.635.222.372.252.00
Inventory Turnover Ratio (X)1.241.241.361.311.19
Dividend Payout Ratio (NP) (%)58.310.0053.5015.3516.64
Dividend Payout Ratio (CP) (%)54.290.0049.6314.9114.55
Earning Retention Ratio (%)41.690.0046.5084.6583.36
Cash Earning Retention Ratio (%)45.710.0050.3785.0985.45
Interest Coverage Ratio (X)39.7496.57102.1821.6121.51
Interest Coverage Ratio (Post Tax) (X)28.6074.0869.7016.7116.31
Enterprise Value (Cr.)591.93644.85795.42154.9612.31
EV / Net Operating Revenue (X)2.842.723.520.820.07
EV / EBITDA (X)18.3016.1727.316.601.11
MarketCap / Net Operating Revenue (X)3.543.213.631.110.28
Retention Ratios (%)41.680.0046.4984.6483.35
Price / BV (X)3.954.786.681.830.44
Price / Net Operating Revenue (X)3.543.213.631.110.28
EarningsYield0.030.030.020.080.17

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Jagsonpal Pharmaceuticals Ltd as of November 22, 2024 is: 570.56

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 22, 2024, Jagsonpal Pharmaceuticals Ltd is Overvalued by 3.78% compared to the current share price 593.00

Intrinsic Value of Jagsonpal Pharmaceuticals Ltd as of November 22, 2024 is: 737.43

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 22, 2024, Jagsonpal Pharmaceuticals Ltd is Undervalued by 24.36% compared to the current share price 593.00

Last 5 Year EPS CAGR: 29.25%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (110.85 cr) compared to borrowings (15.62 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (172.46 cr) and profit (12.54 cr) over the years.
  1. The stock has a low average ROCE of 9.58%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 109.42, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 185.25, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jagsonpal Pharmaceuticals Ltd:
    1. Net Profit Margin: 10.76%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 15.5% (Industry Average ROCE: 16.4%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 11.98% (Industry Average ROE: 16.92%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 28.6
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 9.63
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 58.5 (Industry average Stock P/E: 54.2)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 226.10 Cr. and Equity Capital is Rs. 13.10 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsT-210 J, Shahpur Jat, New Delhi Delhi 110049cs@jagsonpal.com
http://www.jagsonpal.com
Management
NamePosition Held
Mr. Rajpal Singh KochharChairman Emeritus
Mr. Harsha RaghavanChairman & Non-Exe.Director
Mr. Manish GuptaManaging Director
Mr. Prithipal Singh KochharNon Executive Director
Mr. Debasis Bikash NandyIndependent Director
Ms. Radhika Madhukar DudhatIndependent Director
Ms. Pallavi Dinodia GuptaIndependent Director

FAQ

What is the latest intrinsic value of Jagsonpal Pharmaceuticals Ltd?

The latest intrinsic value of Jagsonpal Pharmaceuticals Ltd as on 21 November 2024 is ₹570.56, which is 3.78% lower than the current market price of ₹593.00.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

The Market Cap of Jagsonpal Pharmaceuticals Ltd is 1,565 Cr..

What is the current Stock Price of Jagsonpal Pharmaceuticals Ltd as on 21 November 2024?

The current stock price of Jagsonpal Pharmaceuticals Ltd as on 21 November 2024 is ₹593.

What is the High / Low of Jagsonpal Pharmaceuticals Ltd stocks in FY 2024?

In FY 2024, the High / Low of Jagsonpal Pharmaceuticals Ltd stocks is 635/270.

What is the Stock P/E of Jagsonpal Pharmaceuticals Ltd?

The Stock P/E of Jagsonpal Pharmaceuticals Ltd is 58.5.

What is the Book Value of Jagsonpal Pharmaceuticals Ltd?

The Book Value of Jagsonpal Pharmaceuticals Ltd is 74.4.

What is the Dividend Yield of Jagsonpal Pharmaceuticals Ltd?

The Dividend Yield of Jagsonpal Pharmaceuticals Ltd is 0.84 %.

What is the ROCE of Jagsonpal Pharmaceuticals Ltd?

The ROCE of Jagsonpal Pharmaceuticals Ltd is 17.0 %.

What is the ROE of Jagsonpal Pharmaceuticals Ltd?

The ROE of Jagsonpal Pharmaceuticals Ltd is 13.0 %.

What is the Face Value of Jagsonpal Pharmaceuticals Ltd?

The Face Value of Jagsonpal Pharmaceuticals Ltd is 5.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Jagsonpal Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE